Share Price and Basic Stock Data
Last Updated: January 7, 2026, 6:00 pm
| PEG Ratio | 3.31 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Beta Drugs Ltd, operating in the pharmaceuticals sector, reported a current price of ₹1,643 and a market capitalization of ₹1,658 Cr. The company has shown robust revenue growth, with sales rising from ₹51 Cr in March 2018 to ₹386 Cr in the trailing twelve months (TTM). This upward trajectory reflects a compounded annual growth rate (CAGR) of approximately 60% over the past seven years. The sales figures for FY 2025 stood at ₹362 Cr, indicating a continued positive trend. Quarterly sales have also seen significant increases, with a rise from ₹115 Cr in March 2023 to ₹141 Cr in September 2023. Notably, the operating profit margin (OPM) has remained relatively stable around 20%, showcasing the company’s ability to manage costs effectively while expanding its revenue base. As Beta Drugs continues to capitalize on growth opportunities in the pharmaceutical industry, its revenue trends suggest a strong market position and increasing demand for its products.
Profitability and Efficiency Metrics
Beta Drugs Ltd has demonstrated strong profitability metrics, with a reported net profit of ₹42 Cr for FY 2025, resulting in an earnings per share (EPS) of ₹42.02. The return on equity (ROE) stood at an impressive 25.9%, while the return on capital employed (ROCE) was recorded at 27.0%. These figures indicate effective management of equity and capital, contributing to superior profitability relative to industry standards. The company maintained an operating profit margin (OPM) of 20%, reflecting efficient operational management amid rising expenses, which peaked at ₹288 Cr for FY 2025. The interest coverage ratio (ICR) of 11.60x signifies a strong capacity to meet interest obligations, further enhancing the company’s financial health. However, the cash conversion cycle (CCC) of 79 days indicates a need for improvement in working capital management, which could enhance liquidity and operational efficiency.
Balance Sheet Strength and Financial Ratios
As of the latest reporting, Beta Drugs Ltd’s balance sheet reflects a solid financial foundation, with total assets amounting to ₹436 Cr and total liabilities at ₹488 Cr. The company reported reserves of ₹211 Cr, which have consistently increased over the years, showcasing a commitment to retaining earnings for future growth. Borrowings stood at ₹146 Cr, presenting a debt-to-equity ratio of 0.67, which is moderate and indicates prudent leverage. The current ratio of 3.22x suggests a robust liquidity position, enabling the company to meet short-term obligations comfortably. Additionally, the price-to-book value (P/BV) ratio of 9.76x indicates a premium valuation, which may reflect investor confidence in the company’s growth prospects. However, the increasing debt levels should be monitored closely, as they could pose risks if not managed effectively in relation to cash flows.
Shareholding Pattern and Investor Confidence
Beta Drugs Ltd’s shareholding pattern reveals a strong promoter holding of 66.73%, which indicates significant insider confidence in the company’s future. Foreign institutional investors (FIIs) have gradually increased their stake from 0.29% in early 2023 to 0.90% by March 2025, reflecting growing interest from international investors. Domestic institutional investors (DIIs) have also shown a slight uptick, rising from 0.04% to 0.17% during the same period. The public shareholding stood at 32.07%, with a total of 3,184 shareholders as of September 2025. This diverse ownership structure could enhance the company’s governance and decision-making processes. Nevertheless, the relatively low institutional ownership may indicate a potential risk as it could affect stock liquidity and price stability in volatile market conditions.
Outlook, Risks, and Final Insight
Looking ahead, Beta Drugs Ltd is well-positioned to leverage its operational strengths and market opportunities in the pharmaceutical sector. Continued revenue growth, supported by its solid profitability metrics, underpins a favorable outlook. However, potential risks include rising operational expenses and increased competition, which could pressure margins. Additionally, the company’s growing debt levels warrant close scrutiny, especially if cash flows do not improve proportionately. The ongoing enhancement of working capital management will be crucial to maintaining liquidity. In the event of a favorable regulatory environment and successful product launches, Beta Drugs could see accelerated growth. Conversely, adverse market conditions or regulatory challenges could hinder its performance. Overall, the company’s strategic focus on efficiency and profitability will be key to navigating these dynamics.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 214/84.3 | 27.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,631 Cr. | 424 | 479/192 | 95.9 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.5 Cr. | 46.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.1 Cr. | 39.7 | 40.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,857.92 Cr | 1,159.04 | 54.40 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2019 | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 47 | 44 | 51 | 65 | 88 | 96 | 112 | 115 | 141 | 154 | 180 | 182 | 204 |
| Expenses | 37 | 36 | 41 | 51 | 68 | 73 | 86 | 88 | 108 | 127 | 141 | 146 | 163 |
| Operating Profit | 9 | 8 | 11 | 14 | 20 | 23 | 27 | 26 | 33 | 27 | 39 | 36 | 41 |
| OPM % | 20% | 19% | 21% | 22% | 23% | 24% | 24% | 23% | 23% | 18% | 22% | 20% | 20% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 6 |
| Interest | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 7 |
| Depreciation | 2 | 2 | 3 | 4 | 3 | 4 | 5 | 6 | 5 | 4 | 6 | 7 | 8 |
| Profit before tax | 7 | 5 | 7 | 9 | 16 | 18 | 21 | 20 | 27 | 22 | 33 | 24 | 32 |
| Tax % | 27% | 14% | 21% | 30% | 28% | 27% | 25% | 25% | 25% | 25% | 25% | 26% | 25% |
| Net Profit | 5 | 4 | 5 | 7 | 12 | 13 | 16 | 15 | 20 | 17 | 24 | 18 | 24 |
| EPS in Rs | 5.07 | 4.25 | 5.13 | 6.48 | 11.63 | 12.95 | 15.67 | 14.73 | 19.67 | 16.40 | 24.20 | 17.81 | 23.70 |
Last Updated: January 2, 2026, 7:02 am
Below is a detailed analysis of the quarterly data for Beta Drugs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 204.00 Cr.. The value appears strong and on an upward trend. It has increased from 182.00 Cr. (Mar 2025) to 204.00 Cr., marking an increase of 22.00 Cr..
- For Expenses, as of Sep 2025, the value is 163.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 146.00 Cr. (Mar 2025) to 163.00 Cr., marking an increase of 17.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 36.00 Cr. (Mar 2025) to 41.00 Cr., marking an increase of 5.00 Cr..
- For OPM %, as of Sep 2025, the value is 20.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 20.00%.
- For Other Income, as of Sep 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 6.00 Cr., marking an increase of 6.00 Cr..
- For Interest, as of Sep 2025, the value is 7.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Sep 2025, the value is 8.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.00 Cr. (Mar 2025) to 8.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 32.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Mar 2025) to 32.00 Cr., marking an increase of 8.00 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Mar 2025) to 25.00%, marking a decrease of 1.00%.
- For Net Profit, as of Sep 2025, the value is 24.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Mar 2025) to 24.00 Cr., marking an increase of 6.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 23.70. The value appears strong and on an upward trend. It has increased from 17.81 (Mar 2025) to 23.70, marking an increase of 5.89.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:34 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 66 | 91 | 116 | 184 | 227 | 296 | 362 | 386 |
| Expenses | 41 | 54 | 73 | 91 | 141 | 174 | 236 | 288 | 309 |
| Operating Profit | 9 | 12 | 18 | 25 | 43 | 53 | 60 | 75 | 77 |
| OPM % | 19% | 18% | 20% | 21% | 23% | 23% | 20% | 21% | 20% |
| Other Income | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 6 |
| Interest | 1 | 1 | 3 | 2 | 2 | 2 | 3 | 7 | 12 |
| Depreciation | 2 | 3 | 4 | 7 | 7 | 10 | 10 | 13 | 15 |
| Profit before tax | 7 | 8 | 12 | 16 | 34 | 41 | 49 | 57 | 56 |
| Tax % | 1% | -2% | 21% | 27% | 28% | 25% | 25% | 26% | |
| Net Profit | 7 | 8 | 9 | 12 | 25 | 31 | 36 | 42 | 42 |
| EPS in Rs | 7.43 | 8.84 | 9.33 | 11.60 | 24.58 | 30.42 | 36.08 | 42.02 | 41.51 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 14.29% | 12.50% | 33.33% | 108.33% | 24.00% | 16.13% | 16.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | -1.79% | 20.83% | 75.00% | -84.33% | -7.87% | 0.54% |
Beta Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 32% |
| 3 Years: | 25% |
| TTM: | 23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 37% |
| 3 Years: | 23% |
| TTM: | 26% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 87% |
| 3 Years: | 36% |
| 1 Year: | 12% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 27% |
| Last Year: | 26% |
Last Updated: September 5, 2025, 12:45 am
Balance Sheet
Last Updated: January 7, 2026, 3:27 pm
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 24 | 32 | 48 | 59 | 83 | 113 | 148 | 187 | 211 |
| Borrowings | 8 | 20 | 23 | 17 | 21 | 20 | 15 | 138 | 146 |
| Other Liabilities | 9 | 22 | 28 | 31 | 45 | 55 | 82 | 101 | 121 |
| Total Liabilities | 50 | 83 | 107 | 118 | 158 | 198 | 254 | 436 | 488 |
| Fixed Assets | 13 | 18 | 44 | 40 | 55 | 63 | 65 | 89 | 112 |
| CWIP | 1 | 15 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Other Assets | 35 | 50 | 63 | 74 | 102 | 135 | 190 | 347 | 376 |
| Total Assets | 50 | 83 | 107 | 118 | 158 | 198 | 254 | 436 | 488 |
Below is a detailed analysis of the balance sheet data for Beta Drugs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Reserves, as of Sep 2025, the value is 211.00 Cr.. The value appears strong and on an upward trend. It has increased from 187.00 Cr. (Mar 2025) to 211.00 Cr., marking an increase of 24.00 Cr..
- For Borrowings, as of Sep 2025, the value is 146.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 138.00 Cr. (Mar 2025) to 146.00 Cr., marking an increase of 8.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 121.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 101.00 Cr. (Mar 2025) to 121.00 Cr., marking an increase of 20.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 488.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 436.00 Cr. (Mar 2025) to 488.00 Cr., marking an increase of 52.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 112.00 Cr.. The value appears strong and on an upward trend. It has increased from 89.00 Cr. (Mar 2025) to 112.00 Cr., marking an increase of 23.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 376.00 Cr.. The value appears strong and on an upward trend. It has increased from 347.00 Cr. (Mar 2025) to 376.00 Cr., marking an increase of 29.00 Cr..
- For Total Assets, as of Sep 2025, the value is 488.00 Cr.. The value appears strong and on an upward trend. It has increased from 436.00 Cr. (Mar 2025) to 488.00 Cr., marking an increase of 52.00 Cr..
Notably, the Reserves (211.00 Cr.) exceed the Borrowings (146.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 1.00 | -8.00 | -5.00 | 8.00 | 22.00 | 33.00 | 45.00 | -63.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104 | 139 | 128 | 106 | 90 | 101 | 98 | 103 |
| Inventory Days | 37 | 104 | 102 | 100 | 87 | 106 | 122 | 127 |
| Days Payable | 81 | 143 | 119 | 127 | 123 | 139 | 145 | 152 |
| Cash Conversion Cycle | 60 | 100 | 111 | 79 | 53 | 68 | 75 | 79 |
| Working Capital Days | 50 | 40 | 56 | 76 | 61 | 73 | 80 | 82 |
| ROCE % | 18% | 21% | 22% | 36% | 34% | 33% | 27% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 42.02 | 37.90 | 31.95 | 25.82 | 12.20 |
| Diluted EPS (Rs.) | 42.02 | 37.90 | 31.95 | 25.82 | 12.20 |
| Cash EPS (Rs.) | 54.42 | 48.08 | 42.78 | 33.37 | 19.34 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 195.25 | 163.43 | 127.82 | 96.05 | 71.37 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 195.25 | 163.43 | 127.82 | 96.05 | 71.37 |
| Revenue From Operations / Share (Rs.) | 358.96 | 307.59 | 236.24 | 191.22 | 120.79 |
| PBDIT / Share (Rs.) | 80.28 | 63.82 | 56.05 | 45.20 | 26.26 |
| PBIT / Share (Rs.) | 67.89 | 53.65 | 45.22 | 37.65 | 19.11 |
| PBT / Share (Rs.) | 56.44 | 50.71 | 42.70 | 35.68 | 16.59 |
| Net Profit / Share (Rs.) | 42.02 | 37.90 | 31.95 | 25.82 | 12.20 |
| NP After MI And SOA / Share (Rs.) | 42.02 | 37.90 | 31.95 | 25.82 | 12.20 |
| PBDIT Margin (%) | 22.36 | 20.74 | 23.72 | 23.63 | 21.73 |
| PBIT Margin (%) | 18.91 | 17.44 | 19.14 | 19.69 | 15.81 |
| PBT Margin (%) | 15.72 | 16.48 | 18.07 | 18.65 | 13.73 |
| Net Profit Margin (%) | 11.70 | 12.32 | 13.52 | 13.50 | 10.09 |
| NP After MI And SOA Margin (%) | 11.70 | 12.32 | 13.52 | 13.50 | 10.09 |
| Return on Networth / Equity (%) | 21.52 | 23.19 | 24.99 | 26.88 | 17.08 |
| Return on Capital Employeed (%) | 20.54 | 30.43 | 32.10 | 33.24 | 22.09 |
| Return On Assets (%) | 9.72 | 14.33 | 15.48 | 15.72 | 9.97 |
| Long Term Debt / Equity (X) | 0.64 | 0.03 | 0.05 | 0.12 | 0.16 |
| Total Debt / Equity (X) | 0.67 | 0.06 | 0.13 | 0.17 | 0.21 |
| Asset Turnover Ratio (%) | 1.05 | 1.31 | 1.27 | 1.09 | 0.82 |
| Current Ratio (X) | 3.22 | 2.10 | 2.03 | 1.98 | 1.99 |
| Quick Ratio (X) | 2.64 | 1.51 | 1.54 | 1.52 | 1.53 |
| Inventory Turnover Ratio (X) | 6.61 | 4.17 | 4.16 | 5.70 | 4.47 |
| Interest Coverage Ratio (X) | 11.60 | 21.76 | 22.31 | 22.88 | 10.43 |
| Interest Coverage Ratio (Post Tax) (X) | 7.72 | 13.92 | 13.72 | 14.07 | 5.85 |
| Enterprise Value (Cr.) | 1909.20 | 1168.47 | 599.62 | 542.92 | 119.61 |
| EV / Net Operating Revenue (X) | 5.27 | 3.95 | 2.64 | 2.95 | 1.03 |
| EV / EBITDA (X) | 23.56 | 19.04 | 11.13 | 12.49 | 4.74 |
| MarketCap / Net Operating Revenue (X) | 5.31 | 4.01 | 2.65 | 2.96 | 0.99 |
| Price / BV (X) | 9.76 | 7.55 | 4.90 | 5.89 | 1.68 |
| Price / Net Operating Revenue (X) | 5.31 | 4.01 | 2.65 | 2.96 | 0.99 |
| EarningsYield | 0.02 | 0.03 | 0.05 | 0.04 | 0.10 |
After reviewing the key financial ratios for Beta Drugs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 42.02. This value is within the healthy range. It has increased from 37.90 (Mar 24) to 42.02, marking an increase of 4.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is 42.02. This value is within the healthy range. It has increased from 37.90 (Mar 24) to 42.02, marking an increase of 4.12.
- For Cash EPS (Rs.), as of Mar 25, the value is 54.42. This value is within the healthy range. It has increased from 48.08 (Mar 24) to 54.42, marking an increase of 6.34.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 195.25. It has increased from 163.43 (Mar 24) to 195.25, marking an increase of 31.82.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 195.25. It has increased from 163.43 (Mar 24) to 195.25, marking an increase of 31.82.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 358.96. It has increased from 307.59 (Mar 24) to 358.96, marking an increase of 51.37.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 80.28. This value is within the healthy range. It has increased from 63.82 (Mar 24) to 80.28, marking an increase of 16.46.
- For PBIT / Share (Rs.), as of Mar 25, the value is 67.89. This value is within the healthy range. It has increased from 53.65 (Mar 24) to 67.89, marking an increase of 14.24.
- For PBT / Share (Rs.), as of Mar 25, the value is 56.44. This value is within the healthy range. It has increased from 50.71 (Mar 24) to 56.44, marking an increase of 5.73.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 42.02. This value is within the healthy range. It has increased from 37.90 (Mar 24) to 42.02, marking an increase of 4.12.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 42.02. This value is within the healthy range. It has increased from 37.90 (Mar 24) to 42.02, marking an increase of 4.12.
- For PBDIT Margin (%), as of Mar 25, the value is 22.36. This value is within the healthy range. It has increased from 20.74 (Mar 24) to 22.36, marking an increase of 1.62.
- For PBIT Margin (%), as of Mar 25, the value is 18.91. This value is within the healthy range. It has increased from 17.44 (Mar 24) to 18.91, marking an increase of 1.47.
- For PBT Margin (%), as of Mar 25, the value is 15.72. This value is within the healthy range. It has decreased from 16.48 (Mar 24) to 15.72, marking a decrease of 0.76.
- For Net Profit Margin (%), as of Mar 25, the value is 11.70. This value exceeds the healthy maximum of 10. It has decreased from 12.32 (Mar 24) to 11.70, marking a decrease of 0.62.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 11.70. This value is within the healthy range. It has decreased from 12.32 (Mar 24) to 11.70, marking a decrease of 0.62.
- For Return on Networth / Equity (%), as of Mar 25, the value is 21.52. This value is within the healthy range. It has decreased from 23.19 (Mar 24) to 21.52, marking a decrease of 1.67.
- For Return on Capital Employeed (%), as of Mar 25, the value is 20.54. This value is within the healthy range. It has decreased from 30.43 (Mar 24) to 20.54, marking a decrease of 9.89.
- For Return On Assets (%), as of Mar 25, the value is 9.72. This value is within the healthy range. It has decreased from 14.33 (Mar 24) to 9.72, marking a decrease of 4.61.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.64. This value is within the healthy range. It has increased from 0.03 (Mar 24) to 0.64, marking an increase of 0.61.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.67. This value is within the healthy range. It has increased from 0.06 (Mar 24) to 0.67, marking an increase of 0.61.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.05. It has decreased from 1.31 (Mar 24) to 1.05, marking a decrease of 0.26.
- For Current Ratio (X), as of Mar 25, the value is 3.22. This value exceeds the healthy maximum of 3. It has increased from 2.10 (Mar 24) to 3.22, marking an increase of 1.12.
- For Quick Ratio (X), as of Mar 25, the value is 2.64. This value exceeds the healthy maximum of 2. It has increased from 1.51 (Mar 24) to 2.64, marking an increase of 1.13.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.61. This value is within the healthy range. It has increased from 4.17 (Mar 24) to 6.61, marking an increase of 2.44.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 11.60. This value is within the healthy range. It has decreased from 21.76 (Mar 24) to 11.60, marking a decrease of 10.16.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.72. This value is within the healthy range. It has decreased from 13.92 (Mar 24) to 7.72, marking a decrease of 6.20.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,909.20. It has increased from 1,168.47 (Mar 24) to 1,909.20, marking an increase of 740.73.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.27. This value exceeds the healthy maximum of 3. It has increased from 3.95 (Mar 24) to 5.27, marking an increase of 1.32.
- For EV / EBITDA (X), as of Mar 25, the value is 23.56. This value exceeds the healthy maximum of 15. It has increased from 19.04 (Mar 24) to 23.56, marking an increase of 4.52.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.31. This value exceeds the healthy maximum of 3. It has increased from 4.01 (Mar 24) to 5.31, marking an increase of 1.30.
- For Price / BV (X), as of Mar 25, the value is 9.76. This value exceeds the healthy maximum of 3. It has increased from 7.55 (Mar 24) to 9.76, marking an increase of 2.21.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.31. This value exceeds the healthy maximum of 3. It has increased from 4.01 (Mar 24) to 5.31, marking an increase of 1.30.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Beta Drugs Ltd:
- Net Profit Margin: 11.7%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 20.54% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 21.52% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.72
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.64
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 36.6 (Industry average Stock P/E: 54.4)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.67
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.7%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Village Nandpur, Baddi Himachal Pradesh 174101 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rahul Batra | Chairperson & Managing Director |
| Mr. Varun Batra | Joint Managing Director |
| Mr. Ashutosh Shukla | Whole Time Director |
| Mr. Balwant Singh | Whole Time Director |
| Mr. Ajay Mahipal | Director |
| Mr. Manmohan Khanna | Independent Director |
| Mr. Rohit Parti | Independent Director |
| Mrs. Monica Jain | Independent Director |
| Mr. Sanjay Sehgal | Independent Director |
| Mr. Lalit Kumar Watts | Independent Director |
FAQ
What is the intrinsic value of Beta Drugs Ltd?
Beta Drugs Ltd's intrinsic value (as of 07 January 2026) is ₹1694.01 which is 3.10% higher the current market price of ₹1,643.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,658 Cr. market cap, FY2025-2026 high/low of ₹2,000/1,430, reserves of ₹211 Cr, and liabilities of ₹488 Cr.
What is the Market Cap of Beta Drugs Ltd?
The Market Cap of Beta Drugs Ltd is 1,658 Cr..
What is the current Stock Price of Beta Drugs Ltd as on 07 January 2026?
The current stock price of Beta Drugs Ltd as on 07 January 2026 is ₹1,643.
What is the High / Low of Beta Drugs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Beta Drugs Ltd stocks is ₹2,000/1,430.
What is the Stock P/E of Beta Drugs Ltd?
The Stock P/E of Beta Drugs Ltd is 36.6.
What is the Book Value of Beta Drugs Ltd?
The Book Value of Beta Drugs Ltd is 219.
What is the Dividend Yield of Beta Drugs Ltd?
The Dividend Yield of Beta Drugs Ltd is 0.00 %.
What is the ROCE of Beta Drugs Ltd?
The ROCE of Beta Drugs Ltd is 27.0 %.
What is the ROE of Beta Drugs Ltd?
The ROE of Beta Drugs Ltd is 25.9 %.
What is the Face Value of Beta Drugs Ltd?
The Face Value of Beta Drugs Ltd is 10.0.